Precigen Inc. (NASDAQ:PGEN) is one of the 10 Stocks Paying Off Big Time. Precigen rallied for a second day on Monday, surging ...

Precigen Inc. (NASDAQ:PGEN) is one of the penny stocks with explosive growth potential. On June 15, Precigen secured FDA orphan drug exclusivity for PAPZIMEOS, a precision medicine treating adult ...

The article " Precigen Q1 Earnings Call Highlights " first appeared on MarketBeat.

This is the only open-market sale by the CFO in the past year, following a long stretch of administrative filings, and leaves him with a direct position valued at ~$2.50 million as of May 28, 2026.

View Precigen Inc PGEN stock quote prices, financial information, real-time forecasts, and company news from CNN.

GERMANTOWN, Md., Aug. 5, 2019 /PRNewswire/ -- Precigen, Inc., a wholly-owned subsidiary of Intrexon Corporation (NASDAQ: XON) and a biopharmaceutical company specializing in the development of ...

Precigen (PGEN) is a biotechnology company that has transitioned from a clinical-stage developer to a commercial rare disease platform following the August 2025 approval of Papzimeous for recurrent ...

Good morning. I'm RK, a senior sell-side biotech analyst at H.C. Wainwright. So -- and we are thrilled to be hosting Precigen for this fireside chat this morning. So 2025 has been a transformational ...

Precigen, Inc. (PGEN) could be a solid choice for investors given its recent upgrade to a Zacks Rank #2 (Buy). This upgrade is essentially a reflection of an upward trend in earnings estimates -- one ...

Insiders who bought US$3.7m worth of Precigen, Inc. (NASDAQ:PGEN) stock in the last year have seen some of their losses recouped as the stock gained 32% last week. However, total losses seen by ...

PAPZIMEOS launch gaining strong momentum with $21.6 million in net product revenue in the first quarter of 2026 reflecting broad-based uptake across the US Patient hub enrollment continues to gain ...